Left Atrial Volume and Cardiovascular Outcomes in Systolic Heart Failure: Effect of Antithrombotic Treatment
Open Access
- 17 July 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 5 (5) , 800-808
Abstract
Aims Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events in HF patients with LA enlargement. We investigated the relationship between LA enlargement and CV outcomes in HF patients and the effect of different antithrombotic treatments. Methods and results Two‐dimensional echocardiography with LA volume index (LAVi) measurement was performed in 1148 patients with systolic HF from the Warfarin versus Aspirin in Reduced Ejection Fraction (WARCEF) trial. Patients were randomized to warfarin or aspirin and followed for 3.4 ± 1.7 years. While the primary aim of the trial was a composite of ischaemic stroke, death, and intracerebral haemorrhage, the present report focuses on the individual CV events, whose incidence was compared across different LAVi and treatment subgroups. After adjustment for demographics and clinical covariates, moderate or severe LA enlargement was significantly associated with total death (hazard ratio 1.6 and 2.7, respectively), CV death (HR 1.7 and 3.3), and HF hospitalization (HR 2.3 and 2.6) but not myocardial infarction (HR 1.0 and 1.4) or ischaemic stroke (1.1 and 1.5). The increased risk was observed in both patients treated with warfarin or aspirin. In warfarin‐treated patients, a time in therapeutic range >60% was associated with lower event rates, and an interaction between LAVi and time in therapeutic range was observed for death (P = 0.034). Conclusions In patients with systolic HF, moderate or severe LA enlargement is associated with death and HF hospitalization despite treatment with antithrombotic medications. The possibility that achieving a more consistent therapeutic level of anticoagulation may decrease the risk of death requires further investigation.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (U01-NS-039143)
- National Institute of Neurological Disorders and Stroke (U01-NS-043975)
- Center for Information Technology (U01‐NS‐039143)
- Center for Information Technology (U01‐NS‐043975)
This publication has 20 references indexed in Scilit:
- Independent Relationship of Left Atrial Size and Mortality in Patients with Heart Failure: An Individual Patient Meta-Analysis of Longitudinal Data (MeRGE Heart Failure)European Journal of Heart Failure, 2009
- Left Atrial Volume, Geometry, and Function in Systolic and Diastolic Heart Failure of Persons ≥65 Years of Age (The Cardiovascular Health Study)The American Journal of Cardiology, 2006
- Usefulness of Left Atrial Volume in Predicting First Congestive Heart Failure in Patients ≥65 Years of Age With Well-Preserved Left Ventricular Systolic FunctionThe American Journal of Cardiology, 2005
- Left Atrial Volume in the Prediction of First Ischemic Stroke in an Elderly Cohort Without Atrial FibrillationMayo Clinic Proceedings, 2004
- Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and womenJACC, 2002
- M-Mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health study)The American Journal of Cardiology, 2001
- Left Atrial Size and the Risk of Ischemic Stroke in an Ethnically Mixed PopulationStroke, 1999
- Incidence of and Risk Factors for Atrial Fibrillation in Older AdultsCirculation, 1997
- Left Atrial Size and the Risk of Stroke and DeathCirculation, 1995
- Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.Circulation, 1994